Skip to content
Screener

Gilead Sciences GILD Cumulative Cost Basis

Cumulative Cost Basis at other companies

Vir Biotechnology, Inc. logo
Vir Biotechnology, Inc.VIR
$103.06M+0.7%
Mirum Pharmaceuticals, Inc. logo
Mirum Pharmaceuticals, Inc.MIRM
$493.74M—
Incyte logo
IncyteINCY
——
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
——
Precigen logo
PrecigenPGEN
——
Tango Therapeutics logo
Tango TherapeuticsTNGX
——

Other financials

Income statement

See full
Revenue$7.8B+10.2%
Gross profit$6.2B+11.5%
Operating income-$10.4B-520%
Net income-$10.5B-636%
EPS (diluted)-$8.45-642%

Balance sheet

See full
Cash & equivalents$3.2B-38.2%
Total debt$26.2B+5.2%
Total equity$11.8B-39.9%
Total assets$49.4B-11.4%

Cash flow

See full
Operating cash flow$3.6B+332%
CapEx$140.0M+30.8%
Free cash flow$3.4B+377%

Valuation

See full
Market cap$162.47B+18.4%
Enterprise value$185.54B+18.2%
P/S5.3×+0.6×

Profitability

See full
Gross margin79.6%+1.1pp
Operating margin-8.2%-36.1pp
Net margin-10.6%-32.5pp
FCF margin42.5%+10.0pp

Returns & leverage

See full
Return on equity-20.6%-53.8pp
Debt / equity2.2×+1.0×
Current ratio1.3×0.0×

Where this comes from

Reported directly by Gilead Sciences in its filing.

Tagged under the XBRL concept us-gaap:PropertyPlantAndEquipmentGross.

The source filing: Gilead Sciences’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 4:13 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0000882095-26-000031
(in millions)June 30, 2026December 31, 2025
Property, plant and equipment$8,707$8,302
Less: accumulated depreciation(2,874)(2,696)
Property, plant and equipment, net$5,833$5,606

Item 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FAQ

What is Gilead Sciences's cumulative cost basis?
Gilead Sciences (GILD) reported cumulative cost basis of $8.71B in Q2 2026.
How has Gilead Sciences's cumulative cost basis changed year-over-year?
Gilead Sciences's cumulative cost basis increased by 7.8% year-over-year, from $8.08B to $8.71B.
What is the long-term trend for Gilead Sciences's cumulative cost basis?
Over 2 years (2020 to 2025), Gilead Sciences's cumulative cost basis has grown at a 102.6% compound annual growth rate (CAGR), from $2.02B to $8.3B.
What does cumulative cost basis mean?
The aggregate historical cost basis of assets or liabilities before adjustments for fair value, impairment, or amortization.

Ask your AI about Gilead Sciences's cumulative cost basis.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude